Tech Company Financing Transactions

Oligomerix Funding Round

Private investors and Wheatley Partners participated in a $2.8 million Series B funding round for Oligomerix. The round was announced on 6/30/2013.

Transaction Overview

Company Name
Announced On
6/30/2013
Transaction Type
Venture Equity
Amount
$2,800,000
Round
Series B
Proceeds Purpose
Funding from the Series B round will allow Oligomerix to rapidly advance its drug discovery programs targeting tau protein oligomers that have recently been shown to be neurotoxic, impair memory formation and cause disease progression in disease models.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1300 Morris Park Ave. 1211
Bronx, NY 10461
USA
Email Address
Overview
OLIGOMERIX Inc., is a biopharmaceutical company focused on developing novel drug discovery targets and therapeutics for Alzheimer's disease and other neurodegenerative disorders. Founded in 2006, OLIGOMERIX has filed patents on tau protein oligomers (soluble aggregates) for drug and biomarker discovery.
Profile
Oligomerix LinkedIn Company Profile
Social Media
Oligomerix Company Twitter Account
Company News
Oligomerix News
Facebook
Oligomerix on Facebook
YouTube
Oligomerix on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
James Moe
  James Moe LinkedIn Profile  James Moe Twitter Account  James Moe News  James Moe on Facebook
Chief Financial Officer
Robert Foerster
  Robert Foerster LinkedIn Profile  Robert Foerster Twitter Account  Robert Foerster News  Robert Foerster on Facebook
Chief Medical Officer
William Erhardt
  William Erhardt LinkedIn Profile  William Erhardt Twitter Account  William Erhardt News  William Erhardt on Facebook
Chief Scientific Officer
Eliot Davidowitz
  Eliot Davidowitz LinkedIn Profile  Eliot Davidowitz Twitter Account  Eliot Davidowitz News  Eliot Davidowitz on Facebook
VP - Marketing
Jack Pasini
  Jack Pasini LinkedIn Profile  Jack Pasini Twitter Account  Jack Pasini News  Jack Pasini on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/30/2013: Sight Machine venture capital transaction
Next: 6/30/2013: Ocular Therapeutix venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary